X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Indoco Remedies with Ingersoll Rand - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

INDOCO REMEDIES vs INGERSOLL RAND - Comparison Results

INDOCO REMEDIES    Change

Indoco Remedies is engaged in the manufacturing and marketing of formulations and active pharmaceutical ingredients (APIs) for domestic as well as the international markets. The company's focus areas include anti-infective, respiratory, anti-diabetic... More

INGERSOLL RAND 
   Change

Ingersoll Rand is a global diversified industrial company, engaged in the business of providing solutions for infrastructure development, industrial solutions, residential solutions and security technologies. Ingersoll-Rand manufactures a wide range ... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    INDOCO REMEDIES INGERSOLL RAND INDOCO REMEDIES/
INGERSOLL RAND
 
P/E (TTM) x 38.2 19.6 195.0% View Chart
P/BV x 3.0 1.7 179.0% View Chart
Dividend Yield % 0.8 1.0 75.3%  

Financials

 INDOCO REMEDIES   INGERSOLL RAND
EQUITY SHARE DATA
    INDOCO REMEDIES
Mar-17
INGERSOLL RAND
Mar-18
INDOCO REMEDIES/
INGERSOLL RAND
5-Yr Chart
Click to enlarge
High Rs360940 38.3%   
Low Rs249652 38.2%   
Sales per share (Unadj.) Rs119.0194.7 61.1%  
Earnings per share (Unadj.) Rs8.428.2 29.7%  
Cash flow per share (Unadj.) Rs15.232.1 47.4%  
Dividends per share (Unadj.) Rs1.606.00 26.7%  
Dividend yield (eoy) %0.50.8 69.6%  
Book value per share (Unadj.) Rs70.7357.5 19.8%  
Shares outstanding (eoy) m92.1531.57 291.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.64.1 62.6%   
Avg P/E ratio x36.428.3 128.9%  
P/CF ratio (eoy) x20.024.8 80.8%  
Price / Book Value ratio x4.32.2 193.6%  
Dividend payout %19.121.3 89.8%   
Avg Mkt Cap Rs m28,08325,128 111.8%   
No. of employees `0006.00.7 869.7%   
Total wages/salary Rs m2,1671,061 204.2%   
Avg. sales/employee Rs Th1,817.08,858.6 20.5%   
Avg. wages/employee Rs Th359.01,528.8 23.5%   
Avg. net profit/employee Rs Th127.71,280.8 10.0%   
INCOME DATA
Net Sales Rs m10,9686,148 178.4%  
Other income Rs m40714 5.6%   
Total revenues Rs m11,0076,862 160.4%   
Gross profit Rs m1,565708 221.1%  
Depreciation Rs m633126 502.2%   
Interest Rs m62-21 -298.6%   
Profit before tax Rs m9091,317 69.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m139428 32.4%   
Profit after tax Rs m771889 86.7%  
Gross profit margin %14.311.5 123.9%  
Effective tax rate %15.332.5 47.0%   
Net profit margin %7.014.5 48.6%  
BALANCE SHEET DATA
Current assets Rs m5,7259,916 57.7%   
Current liabilities Rs m5,4541,593 342.4%   
Net working cap to sales %2.5135.4 1.8%  
Current ratio x1.06.2 16.9%  
Inventory Days Days6246 134.7%  
Debtors Days Days7265 109.9%  
Net fixed assets Rs m5,3071,220 435.2%   
Share capital Rs m184316 58.4%   
"Free" reserves Rs m6,33110,969 57.7%   
Net worth Rs m6,51611,285 57.7%   
Long term debt Rs m1,3230-   
Total assets Rs m11,97012,888 92.9%  
Interest coverage x15.6-62.3 -25.1%   
Debt to equity ratio x0.20-  
Sales to assets ratio x0.90.5 192.1%   
Return on assets %7.06.7 103.3%  
Return on equity %11.87.9 150.2%  
Return on capital %12.411.5 107.9%  
Exports to sales %024.4 0.0%   
Imports to sales %020.7 0.0%   
Exports (fob) Rs mNA1,502 0.0%   
Imports (cif) Rs mNA1,275 0.0%   
Fx inflow Rs m4,5071,502 300.0%   
Fx outflow Rs m1,1411,574 72.5%   
Net fx Rs m3,366-72 -4,680.8%   
CASH FLOW
From Operations Rs m886771 114.9%  
From Investments Rs m-1,706935 -182.4%  
From Financial Activity Rs m1,316-231 -569.8%  
Net Cashflow Rs m4971,475 33.7%  

Share Holding

Indian Promoters % 59.2 0.0 -  
Foreign collaborators % 0.0 74.0 -  
Indian inst/Mut Fund % 12.5 7.2 173.6%  
FIIs % 6.0 0.5 1,200.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.4 18.3 122.4%  
Shareholders   12,805 19,522 65.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare INDOCO REMEDIES With:   GREENPLY IND  CREST VENTURES  TIL LTD  GEOJIT FINANCIAL SERVICES  CHOLAMANDALAM INVEST.  



Today's Market

Sensex Slumps Over 290 Points; Realty and PSU Stocks Witness Selling(Closing)

After opening the day on a negative note, share markets in India continued their downtrend throughout the day and ended in red.

Related Views on News

INGERSOLL RAND Announces Quarterly Results (1QFY19); Net Profit Up 53.1% (Quarterly Result Update)

Aug 13, 2018 | Updated on Aug 13, 2018

For the quarter ended June 2018, INGERSOLL RAND has posted a net profit of Rs 207 m (up 53.1% YoY). Sales on the other hand came in at Rs 2 bn (up 1.8% YoY). Read on for a complete analysis of INGERSOLL RAND's quarterly results.

INGERSOLL RAND Announces Quarterly Results (4QFY18); Net Profit Up 30.1% (Quarterly Result Update)

Jul 19, 2018 | Updated on Jul 19, 2018

For the quarter ended March 2018, INGERSOLL RAND has posted a net profit of Rs 265 m (up 30.1% YoY). Sales on the other hand came in at Rs 1 bn (down 13.0% YoY). Read on for a complete analysis of INGERSOLL RAND's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

In a Crisis, if Petrol Prices Hit Rs 100, This Stock Could Be a Good Buy(The 5 Minute Wrapup)

Sep 6, 2018

The rise in the crude oil price is a major reason for the fall in the market. If crude oil prices keep on rising, what will happen to stocks?

As the Rupee Takes a Record Plunge, These Pharma Stocks Gain the Most(Sector Info)

Sep 5, 2018

Most pharma stocks were trading with gains amid rupee's fresh fall. Does that mean pharma stocks are back in vogue?

Why Arun Jaitley's Demonetisation Defence Doesn't Add Up(Vivek Kaul's Diary)

Sep 5, 2018

The tax collected has gone up a little but the question is at what cost.

The Cream of Small Cap Stocks(Profit Hunter)

Sep 5, 2018

Akin to skimming the cream off milk, one needs to learn to skim the cream off small cap stocks.

The Secret Of Mirae Asset India Equity Fund's Increasing Popularity(Outside View)

Sep 7, 2018

The prudent investment strategies followed at the fund house has helped Mirae Asset India Equity Fund earn a tag of being a consistent performer, which is in turn gaining popularity among investors.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

INDOCO REMEDIES SHARE PRICE


Sep 18, 2018 03:35 PM

TRACK INDOCO REMEDIES

  • Track your investment in INDOCO REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON INDOCO REMEDIES

INDOCO REMEDIES - KITEX GARMENTS COMPARISON

COMPARE INDOCO REMEDIES WITH

MARKET STATS